Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal

Regeneron's experimental weight-loss drug, combined with Novo Nordisk's semaglutide, reduced muscle mass loss by 50% in a study. The trial involved patients using both drugs.

Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance, targeting type 2 inflammation with four antibodies. Regeneron will receive $1B upfront and up to $7B in milestones. They will share development costs and profits equally. The deal builds on their 20-year collaboration, including Dupixent, used by 1.5M patients.

Sanofi and Regeneron Pharmaceuticals agreed to expand their alliance to develop and commercialize new immunology drugs. Regeneron will receive $1 billion upfront and up to $7 billion based on milestones. The companies will share costs and profits. They also settled prior litigation. The deal includes four Regeneron drug candidates and an option for Sanofi's lunsekimig.

Sanofi and Regeneron expanded their antibody collaboration, adding four new long-acting antibodies. Regeneron will receive $1bn upfront and up to $7bn in milestones. They will share development costs and profits equally. Sanofi will lead commercialization, while Regeneron leads R&D. The companies resolved prior disputes. Sanofi's net sales are primarily from pharmaceutical products, with significant U.S. market presence.

Sanofi (SASY) will pay Regeneron $1 billion upfront and up to $7 billion more for a partnership on four new inflammatory disease treatments. The companies will share costs and profits equally, with Regeneron leading development and Sanofi handling global sales. The first drug is in early-stage testing, while others are expected to begin human trials in 2027. The deal also settles a previous legal dispute between the companies.

Regeneron (REGN) and Sanofi expanded their antibody collaboration with a $1 billion upfront deal and potential $7 billion in milestone payments. The agreement adds four long-acting antibodies, with REGN20423 in Phase 1 trials for atopic dermatitis. Companies will share costs and profits equally, with Regeneron leading R&D and Sanofi handling global commercialization. The deal includes an option for Regeneron to add Sanofi’s lunsekimig upon Phase 3 trial completion.